Douglas D. Boyd
Department of Cancer Biology
M.D. Anderson Cancer Center
Houston
Texas 77030
USA
Name/email consistency: high
- Combination of an SRC kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness. Boyd, D.D., Wang, H., Avila, H., Parikh, N.U., Kessler, H., Magdolen, V., Gallick, G.E. Clin. Cancer Res. (2004)
- A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis. Boyd, D.D., Kim, S.J., Wang, H., Jones, T.R., Gallick, G.E. Am. J. Pathol. (2003)









